Brain Metastasis in Gastrointestinal Cancers

Brain metastasis arising from cancers of the gastrointestinal tract represents a rare but clinically devastating complication. Though most gastrointestinal tumours preferentially seed to the liver, lungs and bone, a small proportion ultimately invade the central nervous system. The mechanisms underpinning this tropism involve tumour cell extravasation across the blood–brain barrier, molecular adaptations to the neural microenvironment and interactions with resident glial cells. Incidence varies by primary site and histology, with oesophageal adenocarcinoma and HER2-positive gastro-oesophageal adenocarcinomas showing a marginally higher propensity. Prognosis remains poor, with median survival measured in months, but outcomes can improve after aggressive local therapies. Surgical resection and stereotactic radiosurgery have been associated with prolonged survival in selected patients, especially those with solitary intracranial lesions and no extracranial disease. Systemic therapies, including targeted agents and immune checkpoint inhibitors, are under investigation for their ability to cross the blood–brain barrier or modulate the meningeal microenvironment. Improved screening protocols for high-risk subgroups, as well as biomarkers to guide personalised approaches, are emerging priorities for research and clinical management.

Research from Nature Portfolio

A large retrospective cohort study utilising data from a national cancer registry examined over 59 000 patients with gastric cancer to define the incidence, risk and prognostic factors associated with brain metastasis. The analysis revealed a brain metastasis incidence of 0.62%, with higher odds in males, patients under 60 years, those with concurrent bone and lung involvement, high tumour grade and advanced nodal stage. Surgical resection of the primary lesion conferred a markedly reduced risk of intracranial spread. Median overall survival was 3 months for patients with brain metastases versus 17 months for those without, and worse outcomes correlated with high-grade tumours and antral location. This work underscores the value of large-scale screening to identify individuals at elevated risk and informs stratification for clinical surveillance and early intervention.

Brain Metastasis in Gastrointestinal Cancers publication trend

The graph below shows the total number of articles in brain metastasis in gastrointestinal cancers across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier: A specialised endothelial interface that regulates molecular and cellular passage between the bloodstream and the central nervous system.

Leptomeningeal metastasis: Tumour infiltration of the pia and arachnoid mater, often diagnosed by clinical symptoms and detection of malignant cells or ctDNA in CSF.

Circulating tumour DNA (ctDNA): Fragments of tumour-derived genetic material shed into bodily fluids, used for non-invasive biomarker analysis.

Human epidermal growth factor receptor 2 (HER2): A transmembrane tyrosine kinase receptor whose amplification or overexpression can drive tumour progression and influence metastatic patterns.

Graded Prognostic Assessment (GPA): A scoring system incorporating clinical and biological variables to estimate survival in patients with brain metastases.

References

1. Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer. Journal of Translational Medicine (2023).
2. Analysis of risk factors and prognostic factors of brain metastasis in gastric cancer: a surveillance, epidemiology and end-results database study. Scientific Reports (2023).
3. Brain metastasis from gastric adenocarcinoma: A large comprehensive population-based cohort study on risk factors and prognosis. Frontiers in Oncology (2022).
4. HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. Cancers (2022).